BRAF-targeted strategies and PD-1–blocking immunotherapy are more effective adjuvant therapies than currently approved options for patients with high-risk resectable melanoma. However, choosing the best agent for patients with BRAF-mutated disease remains a challenge.

中文翻译：

---

黑色素瘤药物可有效佐剂

对于高危可切除黑色素瘤患者，BRAF靶向策略和PD-1阻断免疫疗法是比目前批准的方案更有效的辅助疗法。然而，为BRAF突变的患者选择最佳药物仍然是一个挑战。